The Cytel Blog: Perspectives on Enquiry & Evidence

Recently we discussed examining clinical development through a Bayesian lens, in honor of Cytel co-founder Nitin Patel..

It is important to compare competing interventions to determine value of medicines, both from clinical and societal..

I had recently (for the first time) the pleasure and honor to attend a virtual meeting with the FDA, a pre-NDA Type-B..

“We found an optimal design in hours that might have taken months to find using standard methods,” reflected Fabien..

Program and portfolio optimization creates a framework throughout the course of the clinical development journey, that..

Earlier this year, Cytel founder Cyrus Mehta observed that clinical trial design is often treated like an art rather..

Conducting a transparent, targeted and robust benefit-risk assessment of a new drug or product is one of the most..

Anil Golla is Vice President, Functional Service Provision (FSP) at Cytel. After 17 years of working at pharmaceutical..

For decades, statisticians have cultivated methods to optimize and de-risk clinical trials for strong regulatory..